SI3389727T1 - Radioaktivno označeni ligandi PET MGLUR2/3 - Google Patents

Radioaktivno označeni ligandi PET MGLUR2/3

Info

Publication number
SI3389727T1
SI3389727T1 SI201630916T SI201630916T SI3389727T1 SI 3389727 T1 SI3389727 T1 SI 3389727T1 SI 201630916 T SI201630916 T SI 201630916T SI 201630916 T SI201630916 T SI 201630916T SI 3389727 T1 SI3389727 T1 SI 3389727T1
Authority
SI
Slovenia
Prior art keywords
pet ligands
mglur2
radiolabelled
radiolabelled mglur2
ligands
Prior art date
Application number
SI201630916T
Other languages
English (en)
Inventor
Jose Ignacio Andres-Gil
Gool Michiel Luc Maria Van
Guy Maurits R. Bormans
Joost Verbeek
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SI3389727T1 publication Critical patent/SI3389727T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI201630916T 2015-12-18 2016-12-16 Radioaktivno označeni ligandi PET MGLUR2/3 SI3389727T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15201240 2015-12-18
EP16812961.7A EP3389727B1 (en) 2015-12-18 2016-12-16 Radiolabelled mglur2/3 pet ligands
PCT/EP2016/081542 WO2017103182A1 (en) 2015-12-18 2016-12-16 Radiolabelled mglur2/3 pet ligands

Publications (1)

Publication Number Publication Date
SI3389727T1 true SI3389727T1 (sl) 2020-10-30

Family

ID=55023944

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630916T SI3389727T1 (sl) 2015-12-18 2016-12-16 Radioaktivno označeni ligandi PET MGLUR2/3

Country Status (16)

Country Link
US (1) US11033641B2 (sl)
EP (1) EP3389727B1 (sl)
JP (1) JP6927974B2 (sl)
AU (1) AU2016374571B2 (sl)
CA (1) CA3003998A1 (sl)
CY (1) CY1124935T1 (sl)
DK (1) DK3389727T3 (sl)
ES (1) ES2828976T3 (sl)
HR (1) HRP20201372T1 (sl)
HU (1) HUE050665T2 (sl)
LT (1) LT3389727T (sl)
PL (1) PL3389727T3 (sl)
PT (1) PT3389727T (sl)
RS (1) RS60981B1 (sl)
SI (1) SI3389727T1 (sl)
WO (1) WO2017103182A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
ES2727379T3 (es) 2014-12-03 2019-10-15 Janssen Pharmaceutica Nv Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5H)-ona y su uso como moduladores alostéricos negativos de receptores de mGlu2
WO2016087489A1 (en) 2014-12-03 2016-06-09 Janssen Pharmaceutica Nv Radiolabelled mglur2 pet ligands
US11045562B2 (en) 2015-12-18 2021-06-29 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
JP6927974B2 (ja) 2015-12-18 2021-09-01 ヤンセン ファーマシューティカ エヌ．ベー． 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド
AU2018373464B2 (en) 2017-11-24 2022-12-08 Sumitomo Pharma Co., Ltd. 6,7-dihydropyrazolo[1,5-a] pyrazinone derivative and medical use thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0756200B1 (en) 1995-07-26 1999-11-10 Konica Corporation Silver halide color photographic light-sensitive material
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6831074B2 (en) 2001-03-16 2004-12-14 Pfizer Inc Pharmaceutically active compounds
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
WO2005061507A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof
MXPA06014809A (es) 2004-06-21 2007-02-12 Hoffmann La Roche Derivados de pirazol-pirimidina.
WO2006030847A1 (ja) 2004-09-17 2006-03-23 Dainippon Sumitomo Pharma Co., Ltd. 新規二環性ピラゾール誘導体
DE102004054665A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte bi- und tricyclische Pyrazol-Derivate Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
BRPI0607927A2 (pt) 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
BRPI0609719B8 (pt) 2005-03-23 2021-05-25 Hoffmann La Roche derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
WO2007084314A2 (en) 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
EP2049119A2 (en) 2006-06-29 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
PT2155747E (pt) 2007-05-10 2012-12-19 Ge Healthcare Ltd Imidazol(1,2-a)piridinas e compostos relacionados com actividade nos receptores de canabinóides cb2
EP2085390A1 (en) 2008-01-31 2009-08-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors
US9446995B2 (en) 2012-05-21 2016-09-20 Illinois Institute Of Technology Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
EA020114B1 (ru) 2008-03-24 2014-08-29 Новартис Аг Производные арилсульфонамида в качестве ингибиторов матриксной металлопротеазы
WO2009130232A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
US20110230472A1 (en) 2008-08-29 2011-09-22 Shionogi & Co., Ltd. Ring-fused azole derivative having pi3k-inhibiting activity
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5634506B2 (ja) 2009-05-12 2014-12-03 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
CA2815120A1 (en) 2010-11-08 2012-05-18 Jose Ignacio Andres-Gil Radiolabelled mglur2 pet ligands
CA2821972A1 (en) 2010-12-17 2012-06-21 Vanderbilt University Bicyclic triazole and pyrazole lactams as allosteric modulators of mglur5 receptors
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
MY167423A (en) 2011-11-03 2018-08-27 Merck Sharp & Dohme Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
JP2013189395A (ja) 2012-03-14 2013-09-26 Dainippon Sumitomo Pharma Co Ltd ジヒドロピロロピラジノン誘導体
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20130281397A1 (en) 2012-04-19 2013-10-24 Rvx Therapeutics Inc. Treatment of diseases by epigenetic regulation
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2013192350A1 (en) 2012-06-20 2013-12-27 Vanderbilt University Substituted bicyclic aralkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
CA2876979A1 (en) 2012-06-20 2013-12-27 P. Jeffrey Conn Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors
US20130345204A1 (en) 2012-06-20 2013-12-26 Vanderbilt University Substituted bicyclic cycloalkyl pyrazole lactam analogs as allosteric modulators of mglur5 receptors
NZ703162A (en) 2012-07-03 2017-05-26 3-V Biosciences Inc Heterocyclic modulators of lipid synthesis
CN104736140A (zh) 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 用于治疗自闭症的mGlu2/3拮抗剂
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
WO2014207082A1 (en) 2013-06-27 2014-12-31 Janssen R&D Ireland Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
HRP20230546T1 (hr) 2013-06-27 2023-08-04 Pfizer Inc. Heteroaromatski spojevi i njihova upotreba kao dopaminskih d1 liganada
ES2707525T3 (es) 2014-08-01 2019-04-03 Janssen Pharmaceutica Nv Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5H)-ona y su uso como moduladores alostéricos negativos de receptores de mGlu2
JOP20150177B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JOP20150179B1 (ar) 2014-08-01 2021-08-17 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
JO3601B1 (ar) * 2014-08-01 2020-07-05 Janssen Pharmaceutica Nv مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2
CN107001373B (zh) 2014-08-01 2020-01-07 詹森药业有限公司 6,7-二氢吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其作为MGLUR2受体的负向别构调节剂的用途
WO2016087489A1 (en) 2014-12-03 2016-06-09 Janssen Pharmaceutica Nv Radiolabelled mglur2 pet ligands
ES2727379T3 (es) 2014-12-03 2019-10-15 Janssen Pharmaceutica Nv Compuestos de 6,7-dihidropirazolo[1,5-a]pirazin-4(5H)-ona y su uso como moduladores alostéricos negativos de receptores de mGlu2
JP2016124810A (ja) * 2014-12-26 2016-07-11 大日本住友製薬株式会社 新規縮合ピラゾール誘導体およびその医薬用途
US11045562B2 (en) * 2015-12-18 2021-06-29 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
JP6927974B2 (ja) 2015-12-18 2021-09-01 ヤンセン ファーマシューティカ エヌ．ベー． 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド

Also Published As

Publication number Publication date
CA3003998A1 (en) 2017-06-22
PL3389727T3 (pl) 2021-02-08
CY1124935T1 (el) 2022-07-22
EP3389727A1 (en) 2018-10-24
DK3389727T3 (da) 2020-11-02
JP2019502700A (ja) 2019-01-31
EP3389727B1 (en) 2020-08-12
US11033641B2 (en) 2021-06-15
US20200306389A1 (en) 2020-10-01
HRP20201372T1 (hr) 2020-11-27
LT3389727T (lt) 2020-10-12
HUE050665T2 (hu) 2020-12-28
AU2016374571A1 (en) 2018-05-17
PT3389727T (pt) 2020-10-30
JP6927974B2 (ja) 2021-09-01
WO2017103182A1 (en) 2017-06-22
AU2016374571B2 (en) 2021-05-06
ES2828976T3 (es) 2021-05-28
RS60981B1 (sr) 2020-11-30

Similar Documents

Publication Publication Date Title
GB201507594D0 (en) Intamac 1
IL259966B (en) Radiolabelled mglur2/3 pet ligands
RS60981B1 (sr) Radiooznačeni mglur2/3 pet ligandi
GB201513478D0 (en) Pet hideaways
AU5457P (en) JOAe 6656 Aeonium arborium
GB201521157D0 (en) Concept 74
GB201521156D0 (en) Concept 80
GB201521158D0 (en) Concept 82
GB201521164D0 (en) Concept 85
GB201521163D0 (en) Concept 78
GB201614306D0 (en) Concept 129
GB201609657D0 (en) Concept 103
GB201607771D0 (en) Concept 100
GB201607772D0 (en) Concept 101
GB201519992D0 (en) Pantrap Nov 2015
GB201505171D0 (en) Concept 37
GB201505175D0 (en) Concept 40
GB201505151D0 (en) Concept 30
GB201505174D0 (en) Concept 40
GB201505172D0 (en) Concept 38
GB201505180D0 (en) Concept 53
GB201505183D0 (en) Concept 52
GB201505186D0 (en) Concept 51
GB201505115D0 (en) Concept 9
GB201505192D0 (en) Concept 46